Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

May 11, 2023
CompanyHeadquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc.
(Securities code: 4974; Prime Market)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in chargeof PR & IR Department(+81)77-565-6970
https://www.takara-bio.co.jp/

Takara Bio Group Formulated “Medium-Term Management Plan 2026”

Kusatsu/Shiga, Japan – May 11, 2023 – Takara Bio Inc. (Takara Bio) has formulated the Medium-Term
Management Plan 2026 (the “New Medium-Term Management Plan”) for the three-year period ending inFY20261 . The New Medium-Term Management Plan sets forth specific action plans for the last three years ofthe Long-Term Management Plan 2026 formulated in FY2021 ( FY2021 to FY2026; visit our website athttps://ir.takara-bio.co.jp/en/management/plan.html ). Our overall policy under the New Medium-Term
Management Plan is to achieve the quantitative targets of the Long-Term Management Plan 2026 ahead of scheduleand accomplish dramatic growth. Our final-year quantitative targets are operating profit of ¥15,000 million andROE 8%.

The Medium-Term Management Plan 2023 (FY2021 to FY2023 of the previous Medium-Term Management
Plan 2023) had overlapped with the worldwide pandemic of the new Coronavirus. During this period, our group
actively developed and manufactured the new Coronavirus testing-related reagents utilizing our proprietary
technology and aggressively worked to vaccine-related CDMO business. As a result, the previous Medium-TermManagement Plan greatly exceeded our quantitative targets, and our group has been aggressively pursuing R&D
investment, capital investment, and human resources investment in a forward-looking manner for further growth.

Under the New Medium-Term Management Plan, in order to overcome “the Corona Cliff”2 and achieve
dramatic growth, we will reform our business structure, promote the sustainable growth of the Reagents /Instruments business and dramatic growth of CDMO business, and develop platform technology for biologics
development We will develop a new business strategy aimed at becoming a global platform provider responsible
for the infrastructure of the life science industry. In addition, we will create new value and contribute to therealization of a sustainable society through the implementation of our corporate philosophy of “contributing tothe health of humankind through the development of revolutionary biotechnologies such as gene therapy.”

1
2

FY2026 refers to the fiscal year ending March 31, 2026.
The cliff of the business performance with or without the sales of the new Coronavirus testing-relatedproducts.

Overview of the Takara Bio Group “Medium-Term Management Plan 2026” (FY2024 to FY2026)

Name

Takara Bio Group “Medium-Term Management Plan 2026”

TermFY2024 to FY2026

General policy

Achieve dramatic growth ahead of the quantitative targets of the “Long-TermManagement Plan 2026”

Quantitative targets
FY2026

Operating profit: ¥15,000 million
ROE: 8% or more

KPI
FY2026

Net sales: ¥68,100 million
R&D expenses: ¥9,000 million

Business Strategy
Establish a position as a global platform provider of infrastructure in the life science industry



Establishment of a global manufacturing and marketing system

Strengthening of quality control processes and manufacturing technologies

Maximize the value of platform technologies for developing biologics

Accelerate the development speed of new products and services by selecting and focusing on R&D
projects

Strategy for Strengthening the Management Base

Improve ROE by actively investing in growth/strengthening areas and appropriately returning profits tostockholders (financial)Deepen ties between the company and its employees and build a solid foundation for growth (humanresources and organizations)

Achieving a sustainable society and sustainable growth for our group (social value)

Performance Trends (Actual and Forecasts)
Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs that are
not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently available
to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks anduncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence
actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as
exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.